The association of the BDNF Val66Met polymorphism with increased BMI is consistent with earlier findings in schizophrenia patients and suggests that the BDNF Val66Met genotype may be a significant risk factor for obesity and metabolic disturbances in patients with BD, particularly those undergoing antipsychotic treatment. This evidence concerns the gene BDNF and schizophrenia.